Anti-Tuberculosis Therapeutics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type (Active TB, Latent TB, Others), By Diagnosis and Treatment (Diagnosis (Blood Tests, Imaging Tests, Sputum Tests, Others), Treatment (First Line of Drugs, Second Line of Drugs, others), others), By End User (Hospitals, Specialty Clinics, Homecare, others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1411.21 Million
CAGR (2026-2031)	5.94%
Fastest Growing Segment	Active TB
Largest Market	North America
Market Size (2031)	USD 1995.04 Million

Market Overview

The Global Anti-Tuberculosis Therapeutics Market will grow from USD 1411.21 Million in 2025 to USD 1995.04 Million by 2031 at a 5.94% CAGR. Anti-Tuberculosis Therapeutics comprise pharmacological interventions specifically formulated to treat infections caused by Mycobacterium tuberculosis. Market growth is primarily driven by the increasing incidence of tuberculosis in high-burden regions and the critical requirement to address multi-drug resistant strains through advanced treatment protocols. This demand is further supported by robust government initiatives and international funding designed to enhance diagnosis and treatment accessibility globally. According to the World Health Organization’s Global Tuberculosis Report 2024, an estimated 10.8 million individuals fell ill with tuberculosis in 2023, underscoring the urgent and sustained need for effective therapeutic solutions.

A significant challenge impeding market expansion is the escalating prevalence of antimicrobial resistance which compromises the efficacy of standard first-line antibiotics. The emergence of resistant bacterial strains forces healthcare providers to resort to second-line therapies that often entail higher costs, severe toxicity, and prolonged treatment durations. These factors frequently lead to poor patient adherence and place a substantial financial burden on public health systems, thereby restricting the broader adoption of available therapeutic options.

Key Market Drivers

The high prevalence of multi-drug resistant and extensively drug-resistant tuberculosis serves as a primary catalyst for market evolution, necessitating the adoption of advanced pharmacological agents beyond standard first-line regimens. The inefficacy of isoniazid and rifampicin in these cases compels healthcare systems to procure second-line therapeutics and novel combinations like BPaL (bedaquiline, pretomanid, and linezolid) to improve patient outcomes. According to the World Health Organization, October 2024, in the 'Global Tuberculosis Report 2024', an estimated 400,000 people developed multidrug-resistant or rifampicin-resistant tuberculosis in 2023. This specific burden drives the commercial prioritization of premium-priced, patent-protected molecules capable of shortening treatment duration and mitigating the severe toxicity profiles associated with older drug classes, thereby reshaping revenue streams for manufacturers focusing on resistant strains.

Increasing financial commitments from governmental bodies and non-governmental organizations are accelerating the clinical development of next-generation anti-tubercular drugs and vaccines. This influx of capital reduces the economic risk for pharmaceutical developers, fostering a more robust pipeline of candidate therapies designed to tackle complex infection profiles. According to the Stop TB Partnership and Treatment Action Group, December 2024, in the '2024 Report on TB Research Funding Trends', global funding for tuberculosis research and development reached US$1.2 billion in 2023. These investments are critical for scaling manufacturing and distribution capabilities to meet global demand. Underscoring the scale of this therapeutic requirement, according to the World Health Organization, in 2024, the number of people newly diagnosed with tuberculosis reached 8.2 million in 2023, the highest figure recorded since global monitoring began.

Download Free Sample Report

Key Market Challenges

The escalating prevalence of antimicrobial resistance (AMR) presents a substantial barrier to the growth of the global anti-tuberculosis therapeutics market. As Mycobacterium tuberculosis strains develop immunity to standard first-line antibiotics, healthcare providers are forced to rely on second-line pharmacological regimens. These alternative therapies are characterized by significantly higher acquisition costs and increased toxicity profiles compared to standard treatments. Consequently, the elevated financial requirement imposes a severe strain on public health budgets, particularly in high-burden regions, limiting the ability of government programs to procure and distribute these essential medications at scale. This economic pressure, combined with the adverse side effects that discourage patient compliance, directly restricts the broader commercial adoption and volume of advanced therapeutic agents.

The disparity between the critical need for resistance-targeting therapies and their actual deployment is evident in recent data. According to the World Health Organization, in 2025, it was reported that only about two in five people with multidrug-resistant tuberculosis accessed necessary treatment in 2024. This statistic underscores a significant market bottleneck: despite the availability of potent second-line therapeutics, the complexities and resource intensity associated with managing resistant strains prevent these products from reaching a majority of the addressable patient population, thereby hampering the market’s potential for expansion.

Key Market Trends

The widespread adoption of BPaL and BPaLM protocols is rapidly shifting the global standard of care from prolonged injectable regimens to streamlined, six-month all-oral courses. This operational transition allows national health systems to consolidate their therapeutic inventories around bedaquiline, pretomanid, and linezolid, significantly reducing supply chain complexity while enhancing treatment completion rates through simplified administration. The scale of this implementation is reshaping market demand, as evidenced by the velocity of international procurement. According to TB Alliance, January 2025, in the '2024 Annual Report', more than 100,000 courses of the BPaL/M regimen were ordered across approximately 100 countries in 2024, representing the fastest therapeutic rollout in the sector's modern history.

Simultaneously, the development of pediatric-specific dispersible drug formulations is establishing a specialized market segment focused on accurate, child-friendly dosing. Manufacturers are increasingly moving away from the reliance on fractionated adult tablets by engineering palatable, water-soluble options that ensure precise bioavailability for the pediatric demographic. This focus on formulation innovation addresses critical gaps in therapeutic adherence and safety for younger patients. Demonstrating the success of these targeted development efforts, according to TB Alliance, November 2025, in a press release regarding the 'IMPAACT 2034' study, interim data showed that a single dose of a new pediatric dispersible pretomanid formulation achieved pharmacokinetic exposures in children comparable to those in adults.

Segmental Insights

The Active TB segment is emerging as the fastest-growing category within the Global Anti-Tuberculosis Therapeutics Market, driven by the escalating global burden of multidrug-resistant tuberculosis (MDR-TB). This rise in resistant strains has necessitated the development and deployment of advanced, high-value therapeutic regimens, significantly boosting market expansion. Furthermore, global initiatives led by the World Health Organization prioritize the immediate detection and treatment of active cases to interrupt disease transmission chains. This sustained focus on curative interventions for symptomatic patients ensures that Active TB remains the primary engine of market growth.

Regional Insights

North America dominates the Global Anti-Tuberculosis Therapeutics Market largely driven by its robust healthcare infrastructure and extensive investment in research and development. The region hosts major pharmaceutical companies that collaborate with government bodies to advance drug discovery. Notably, the United States Food and Drug Administration supports this growth through favorable regulatory pathways, such as expedited review processes for new treatments. These strategic initiatives, coupled with high healthcare spending and accessible diagnostic services, ensure the effective commercialization of therapeutics, thereby maintaining the region's leading status in the global market.

Recent Developments

• In November 2024, Macleods Pharmaceuticals obtained prequalification from the World Health Organization (WHO) for its pretomanid 200mg tablets. This regulatory validation assures the safety, quality, and efficacy of the therapeutic, which is a critical element of the BPaL and BPaL/M regimens used to treat drug-resistant tuberculosis. The prequalification facilitates the procurement of this essential medicine by international agencies such as the Global Fund and the Stop TB Partnership's Global Drug Facility for distribution in low- and middle-income countries. This development supports the company's efforts to expand global access to shorter, more effective oral treatment regimens for patients in high-burden regions.
• In July 2024, Johnson & Johnson received full approval from the U.S. Food and Drug Administration (FDA) for its multidrug-resistant tuberculosis therapy, bedaquiline. This regulatory milestone transitioned the drug from its previous accelerated approval status to traditional approval, following the submission of confirmatory data from the Phase 3 STREAM Stage 2 study. The trial demonstrated that a bedaquiline-containing all-oral regimen significantly improved treatment outcomes compared to older injectable-containing regimens. Concurrent with the FDA decision, the European Commission converted the drug's conditional marketing authorisation into a standard authorisation, reinforcing its position as a core component of global treatment guidelines for drug-resistant tuberculosis.
• In May 2024, BioVersys expanded its strategic collaboration with GSK to accelerate the clinical development of alpibectir, a novel small molecule designed to treat tuberculosis. This agreement extended an existing partnership and included a new equity investment from GSK into the Swiss biotechnology company. The collaboration focuses on advancing alpibectir through Phase 2a clinical trials for both pulmonary tuberculosis and tuberculosis meningitis. By enhancing the efficacy of the existing antibiotic ethionamide, this candidate aims to overcome drug resistance and enable lower dosages, thereby reducing side effects and providing a more effective option for patients battling resistant strains of the infection.
• In March 2024, Otsuka Pharmaceutical announced positive interim results from a Phase 2b/c clinical trial evaluating its investigational compound, quabodepistat, for the treatment of pulmonary tuberculosis. The study assessed the safety and efficacy of quabodepistat in combination with delamanid and bedaquiline, aiming to identify a regimen that could shorten treatment duration compared to the standard of care. This research, conducted in collaboration with the Bill & Melinda Gates Foundation, indicated that the new combination was well-tolerated and showed potential for treating drug-susceptible forms of the disease. The company plans to continue developing this regimen to improve patient adherence and outcomes globally.

Key Market Players

• AstraZeneca Plc.
• Johnson & Johnson Private Limited
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi SA
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Merck & Co., Inc.

By Disease Type	By Diagnosis and Treatment	By End User	By Region
Active TB Latent TB Others	Diagnosis (Blood Tests, Imaging Tests, Sputum Tests, Others) Treatment (First Line of Drugs, Second Line of Drugs, others) others	Hospitals Specialty Clinics Homecare others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Anti-Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Anti-Tuberculosis Therapeutics Market, By Disease Type:

• Active TB
• Latent TB
• Others

• Anti-Tuberculosis Therapeutics Market, By Diagnosis and Treatment:

• Diagnosis (Blood Tests, Imaging Tests, Sputum Tests, Others)
• Treatment (First Line of Drugs, Second Line of Drugs, others)
• others

• Anti-Tuberculosis Therapeutics Market, By End User:

• Hospitals
• Specialty Clinics
• Homecare
• others

• Anti-Tuberculosis Therapeutics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE